Factor VIII inhibitor and source of replacement therapy by P.M. Mannucci et al.
112
LETTER TO THE EDITOR
In reply
Factor VIII inhibitor and source of replacement therapy
Pier Mannuccio Mannucci1, Alessandro Gringeri2, Elena Santagostino2, Flora Peyvandi2
1Scientifi c Direction; 2Hemophilia and Thrombosis Centre, A. Bianchi Bonomi, IRCCS Ca' Granda Maggiore 
Policlinico Hospital Foundation, Milan, Italy
Blood Transfus 2012; 10: 112-3  DOI 10.2450/2011.0064-11
© SIMTI Servizi Srl
Dear Sir,
In their timely letter on the current state of 
haemophilia therapy, Calizzani and Arcieri1 tackle 
two clinically important points: the effect of the 
source of factor VIII replacement therapy (plasma-
derived or recombinant) on the cumulative incidence 
of factor VIII inhibitors in patients with haemophilia 
A; and whether or not the so-called continuity of care 
with the very coagulation factor product to which 
patients are accustomed is warranted.
As to the fi rst point, and pertaining to the debate 
between Franchini2 and Mannucci3 and the article 
by Gringeri4 on the choice of factor VIII products, 
Calizzani and Arcieri must be reassured that the 
forthcoming therapeutic recommendations of the 
Italian Association of Haemophilia Centres (AICE) 
on the choice of products for replacement therapy will 
be strictly based on the available scientifi c evidence. 
A recent systematic review and meta-analysis found a 
two-fold increased incidence of inhibitors associated 
with the use of recombinant factor VIII5, but the 
difference in favour of plasma-derived factor VIII lost 
its statistical signifi cance when important variables 
such as study design, study period and frequency of 
inhibitor testing were tested as confounders5. Hence, 
there is a state of uncertainty on the effect of the 
source of factor VIII on inhibitor incidence. This state 
of uncertainty (clinical equipoise) is the justifi cation 
for our decision to organise the currently ongoing 
randomized SIPPET study6.
Debates such as those published in this journal2,3 
and other journals on different competing therapies 
inevitably lead the "duelists" to defend vigorously 
one position, and only that one. We are indeed 
convinced that the available data do justify the design 
of the SIPPET study6, based on the hypothesis of a 
lower incidence of inhibitors in patients treated with 
plasma-derived, von Willebrand factor-containing 
factor VIII products. Yet, we are also cognizant that 
this is a working hypothesis, not yet evidence-based: 
otherwise the SIPPET study would be unnecessary!
Pertaining to the so-called continuity of care, we 
agree with Calizzani and Arcieri that this should be 
preserved as much as possible. However, the issue 
is not that switching from one source and/or product 
of factor VIII to another would increase the risk of 
inhibitor. There is so far evidence that switching 
from a plasma-derived to a recombinant product 
or, by the same token, from a recombinant product 
to another does not increase inhibitor incidence in 
previously treated people with haemophilia7-9. For 
plasma-derived factor VIII the only study showing, 
albeit indirectly, that changing products leads to 
a higher cumulative incidence of inhibitors stems 
from the systematic review of Paisley et al.10, with 
a number of other studies showing that switching is 
neutral in this respect7-9. Nevertheless, some large 
cohort studies are ongoing in Europe and in the UK 
(for instance, C. Hay, communication at the 7th Bari 
International Conference, Pugnochiuso, Vieste del 
Gargano, Italy, 21-23 May 2011), which, it is to be 
hoped, will provide a defi nitive answer. While waiting 
for the still unavailable evidence that haemophilia 
care can be personalised11, we are in favour of 
continuity for a different but very important reason: 
the need for a robust pharmacovigilance system. 
Even though all anti-haemophilic products have 
currently reached an unprecedented level of safety, 
pharmacovigilance is still essential, as exemplifi ed 
by the action taken by the European Association of 
Haemophilia and Allied Disorders together with the 
European Haemophilia Consortium in developing and 
fostering the EUHASS project12. Pharmacovigilance 
is also rendered cogent by the ongoing developments 
in DNA technology, which, it is to be hoped, will soon 
make available factor VIII and factor IX products 
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with an extended plasma half-life13. The long-term 
safety of these products, and the current theoretical 
concerns on conjugate tolerogenicity and neo-epitope 
immunogenicity can only be fi rmly established by 
pharmacovigilance programmes such as EUHASS. 
Most importantly, we learnt a lesson from the 
1980s drama of human immunodefi ciency virus and 
hepatitis C virus infections. At that time the limited 
availability of coagulation factor products, which 
often forced us to change products, made it diffi cult 
to identify the lots and products carrying a higher 
risk of viral infections. Another potential reason 
for supporting the so-called "continuity of care" is 
compliance, which can be jeopardised by frequent 
switching among different products. 
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